title: [Application of steroids minimization immunosuppressive regimen in liver transplantation].
abstract: OBJECTIVE
  To investigate the safety and feasibility of steroids minimization immunosuppressive regimen in liver transplantation.
  
  
  METHODS
  One hundred and sixteen patients in line with the selecting criteria from January 2005 to June 2008 were divided into three groups according to the withdrawal of steroids: 40 cases in 3 months withdrawal group, 40 cases in 7 d withdrawal group and the other 36 cases in 24 h withdrawal group. The difference of recipients' survival, infection, acute rejection and steroids resistant acute rejection, wound healing, recurrence of HBV and hepatocellular cell (HCC), new on-set of diabetes, hyperlipidemia and hypertension between the three groups were compared.
  
  
  RESULTS
  The difference of recipients' survival, acute rejection including steroids resistant acute rejection, recurrence of HBV and HCC, hyperlipidemia between the three groups were not significant (P > 0.05), the incidence of wound un-healing and hypertension in 24 h withdrawal group was significantly lower than that in the other 2 groups (P < 0.05), the incidence of infection and new on-set diabetes in 24 h withdrawal group and 7 d withdrawal group was significantly lower than that in 3 months withdrawal group (P < 0.05).
  
  
  CONCLUSIONS
  Steroids minimization immunosuppressive strategy is safe and feasible in liver transplantation field, it will significantly reduce the steroids related complications without increasing the risk of rejection.
authors.affiliation: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
authors.forename: Lin-wei
authors.initials: LW
authors.lastname: Wu
authors.forename: Xiao-shun
authors.initials: XS
authors.lastname: He
authors.forename: Qiang
authors.initials: Q
authors.lastname: Tai
authors.forename: Wei-qiang
authors.initials: WQ
authors.lastname: Ju
authors.forename: Dong-ping
authors.initials: DP
authors.lastname: Wang
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Zhu
authors.forename: Yi
authors.initials: Y
authors.lastname: Ma
authors.forename: Guo-dong
authors.initials: GD
authors.lastname: Wang
authors.forename: An-bin
authors.initials: AB
authors.lastname: Hu
authors.forename: Jie-fu
authors.initials: JF
authors.lastname: Huang
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D013256:Steroids / Q000008:administration & dosage* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids